BRIEF-Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers

Seaport Therapeutics

Seaport Therapeutics

SPTX

0.00

June 8 (Reuters) - Seaport Therapeutics Inc SPTX.O:

  • SEAPORT THERAPEUTICS REPORTS POSITIVE MULTIPLE-ASCENDING DOSE DATA FROM PHASE 1 PROOF-OF-CONCEPT TRIAL OF GLYPHAGO™ IN HEALTHY VOLUNTEERS

  • SEAPORT THERAPEUTICS - REPEAT DOSING OF GLYPHAGO SHOWS FAVORABLE SAFETY AND NO LIVER-RELATED ADVERSE EVENTS

  • SEAPORT THERAPEUTICS - SEVEN-DAY GLYPHAGO DOSING ACHIEVES THERAPEUTIC AGOMELATINE EXPOSURES WITHOUT LIVER ENZYME ELEVATIONS

  • SEAPORT THERAPEUTICS - TO INITIATE PHASE 2A GLYPHAGO TRIAL IN SECOND HALF OF 2026

  • SEAPORT THERAPEUTICS - TO INITIATE PHASE 2B GLYPHAGO TRIAL IN FIRST HALF OF 2027

Source text: ID:nBw3W9JFFa

Further company coverage: SPTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.